We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Rituximab in Children and Adolescents With Relapsed and Refractory B-Cell NHL/L3ALL

This study has been terminated.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00180895
First Posted: September 16, 2005
Last Update Posted: September 11, 2006
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Hoffmann-La Roche
Information provided by:
Gustave Roussy, Cancer Campus, Grand Paris
  Purpose
This is a multicentric phase II study of Mabthera (rituximab) in children and adolescents with relapsed and refractory B-cell NHL/L3ALL. The primary objective is to determine the response rate of Rituximab as single agent in relapsed or refractory Burkitt lymphoma, L3 acute leukemia, large B-cell lymphoma and non subclassified aggressive B-cell NHL

Condition Intervention Phase
Burkitt Lymphoma Drug: Rituximab Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of Mabthera (Rituximab) in Children and Adolescents With Relapsed and Refractory B-Cell NHL/L3ALL

Resource links provided by NLM:


Further study details as provided by Gustave Roussy, Cancer Campus, Grand Paris:

Primary Outcome Measures:
  • Rate of patients achieving at least objective response after 2 courses of rituximab

Secondary Outcome Measures:
  • Rate of objective response after 4 courses of rituximab
  • Rate of initially responding patients who progressed during the second phase of treatment
  • Toxicity
  • Pharmacokinetic evaluation in serum and CSF

Estimated Enrollment: 40
Study Start Date: June 2004
Detailed Description:

This is a multicentric phase II study of Mabthera (rituximab) in children and adolescents with relapsed and refractory B-cell NHL/L3ALL. The primary objective is to determine the response rate of Rituximab as single agent in relapsed or refractory Burkitt lymphoma, L3 acute leukemia, diffuse large B-cell lymphoma and non subclassified aggressive B-cell NHL. The secondary objectives are to assess the toxicity profile of Rituximab in children and adolescents as single agent, and when followed by chemotherapy, to study pharmacokinetics of Rituximab in serum and in CSF and to determine the overall duration of response, time to progression and survival in patients responders to antiCD20 initially alone and followed by chemotherapy.

Patients will receive Rituximab (Mabthera) at 375 mg/m2, once a week during 4 weeks, administered in IV infusion starting at 50mg/h and increasing by steps of 50 mg/h every 30mn until the speed of 400 mg/h. Patients with combined CNS relapse will receive an intrathecal injection of MTX+HC+Ara-C 48 h after each injection of rituximab First assessment will be done prior to receiving the 3rd course of rituximab. Responding patients (CR, PR) and patients with objective effect (OE) will receive the 3rd and 4th injections of rituximab before starting the salvage chemotherapy (COPADM, CYVE/CC course or ICE, depending on previous chemotherapy regimen received by the patient, followed by HDCT+ hematopoietic stem cell rescue). A second evaluation will be done after the 4th course if performed.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   6 Months to 20 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically or cytologically proven B-cell malignancies, either Burkitt NHL or L3 ALL or large B-cell lymphoma or aggressive B-cell NHL, with the exception of diffuse large B-cell lymphoma arising in the mediastinum.
  • Immunohistochemistry showing CD20 positivity
  • Measurable (at least one bi-dimensionally measurable lesion) or evaluable (bone marrow, bone involvement) disease in progression since the last evaluation
  • First relapsed or refractory disease after LMB or BFM protocol, except the isolated CNS relapses
  • Life expectancy > 4 weeks
  • Performance status (Karnofsky) > 30
  • Adequate hepatic, renal and cardiac functions
  • Wash out of 3 weeks in case of recent chemotherapy
  • Complete initial work-up within 8 days prior to treatment
  • Able to comply with scheduled follow-up and with management of toxicity
  • Written inform consent form from adult patients and from parents and legal guardians for minor children

Exclusion Criteria:

  • Active viral infection, especially chronic hepatitis B
  • previous salvage therapy for relapse
  • Prior or current history of severe allergy
  • Primary large B-cell lymphoma of the mediastinum
  • Isolated CNS relapse
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00180895


Locations
France
Institut Gustave Roussy
Villejuif, France, 94800
Sponsors and Collaborators
Gustave Roussy, Cancer Campus, Grand Paris
Hoffmann-La Roche
Investigators
Principal Investigator: Catherine Patte, MD Gustave Roussy, Cancer Campus, Grand Paris
  More Information

ClinicalTrials.gov Identifier: NCT00180895     History of Changes
Other Study ID Numbers: Rituximab childhood
First Submitted: September 12, 2005
First Posted: September 16, 2005
Last Update Posted: September 11, 2006
Last Verified: September 2006

Keywords provided by Gustave Roussy, Cancer Campus, Grand Paris:
Burkitt lymphoma
B-cell non Hodgkin lymphoma
B-cell ALL
Refractory
Relapse
Rituximab
Children

Additional relevant MeSH terms:
Burkitt Lymphoma
Epstein-Barr Virus Infections
Herpesviridae Infections
DNA Virus Infections
Virus Diseases
Tumor Virus Infections
Lymphoma, B-Cell
Lymphoma, Non-Hodgkin
Lymphoma
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Rituximab
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents